Imimart 500 Injection is a combination antibiotic formulation containing Imipenem 500 mg and Cilastatin 500 mg, indicated for the treatment of serious bacterial infections caused by susceptible organisms. Imipenem, a broad-spectrum carbapenem antibiotic, exerts bactericidal activity by inhibiting bacterial cell wall synthesis, thereby disrupting cell integrity and leading to cell death. Cilastatin is a renal dehydropeptidase inhibitor that prevents the enzymatic degradation of Imipenem in the kidneys, enhancing its bioavailability and therapeutic efficacy. This combination is effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic pathogens, including resistant strains. Imimart 500 Injection is commonly utilized in the management of complicated urinary tract infections, intra-abdominal infections, skin and soft tissue infections, pneumonia, and septicemia. The dosage and duration of therapy should be determined based on the severity of infection, renal function, and patient response. Administration is via intravenous infusion, with careful monitoring for potential adverse reactions such as hypersensitivity, gastrointestinal disturbances, and central nervous system effects including seizures, particularly in patients with predisposing factors. Imimart 500 Injection should be used under strict medical supervision, with attention to appropriate antimicrobial stewardship to prevent resistance development.